{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    8,
    9,
    19,
    22,
    23,
    33,
    34,
    36,
    38,
    41,
    42,
    44,
    46,
    55
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Prior and Concomitant DMARD Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3.1",
        "sectionTitle": "Prior Therapy",
        "description": "Reference for additional details related to prior DMARD therapy"
      },
      {
        "id": "ref_2",
        "name": "Concomitant DMARD Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3.2",
        "sectionTitle": "Permitted Background Therapy",
        "description": "Reference for additional details related to concomitant DMARD therapy"
      },
      {
        "id": "ref_3",
        "name": "Maximum Doses Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3.3",
        "sectionTitle": "Prohibited Therapy",
        "description": "Reference for maximum doses of background PsA medications"
      },
      {
        "id": "ref_4",
        "name": "Discontinuation Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.1",
        "sectionTitle": "Discontinuation of Individual Subjects",
        "description": "Reference for details on subjects choosing to continue study participation after drug discontinuation"
      },
      {
        "id": "ref_5",
        "name": "TB Testing Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.1.1",
        "sectionTitle": "Study Procedures",
        "description": "Reference for specific requirements for TB testing and exclusionary parameters"
      },
      {
        "id": "ref_6",
        "name": "CYP3A Inhibitors Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Examples of Commonly Used Strong CYP3A Inhibitors and Inducers",
        "description": "Reference for examples of strong CYP3A inhibitors and inducers"
      },
      {
        "id": "ref_7",
        "name": "Screening Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix C",
        "sectionTitle": "Study Activities",
        "description": "Reference for screening procedures outline"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided within the clinical trial agreement.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Upon approval of protocol amendment 8, subjects receiving upadacitinib 30 mg QD will be switched to upadacitinib 15 mg QD at their next scheduled study visit.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Design Figure 1",
        "pageNumber": 37
      },
      {
        "id": "annot_3",
        "text": "Subjects with a borderline serum pregnancy test at Screening must have a serum pregnancy test â‰¥ 3 days later to document continued lack of a positive result.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Inclusion Criteria",
        "pageNumber": 42
      },
      {
        "id": "annot_4",
        "text": "At Week 16 rescue therapy will be offered to subjects classified as non-responders.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Design",
        "pageNumber": 37
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "8.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-01-29",
        "description": "Incorporating Administrative Changes 1, 2 and Amendments 1 through 8; includes dose switch from 30mg to 15mg.",
        "amendmentNumber": "Amendment 8"
      },
      {
        "id": "ver_2",
        "versionNumber": "7.01",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-07-23",
        "description": "Specific to Belgium, Czech Republic, France, Greece, Hungary, Japan, New Zealand, and Portugal.",
        "amendmentNumber": "Amendment 7.01"
      },
      {
        "id": "ver_3",
        "versionNumber": "7.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-04-01",
        "description": "Previous protocol version",
        "amendmentNumber": "Amendment 7"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}